m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02050)
Name
AKB-9778
Status
Phase 2
Structure
Formula
C26H26N4O6S3
InChI
1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
InChIKey
KWJDHELCGJFUHW-SFTDATJTSA-N
PubChem CID
46700782
TTD Drug ID
D08VIS
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Angiopoietin 1 receptor (TEK)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Angiopoietin 1 receptor (TEK) is a therapeutic target for AKB-9778. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AKB-9778 through regulating the expression of Angiopoietin 1 receptor (TEK). [1], [2]
References
Ref 1 Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis. Front Cell Dev Biol. 2021 Feb 18;9:627706. doi: 10.3389/fcell.2021.627706. eCollection 2021.
Ref 2 The contribution of inositol 1,4,5-trisphosphate and ryanodine receptors to agonist-induced Ca(2+) signaling of airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L347-61. doi: 10.1152/ajplung.90559.2008. Epub 2009 May 22.